Objectives: Mesenchymal stem cells (MSCs) are frequently delivered via needle injection for treatment of musculoskeletal injuries. The purpose of this study was to evaluate the effect of needle diameter on the viability of MSCs.
| I N T R O D U C T I O N
Mesenchymal stem cells (MSCs) are frequently used to treat musculoskeletal injuries in the horse. [1] [2] [3] [4] [5] [6] The most common clinical application of MSCs in the equine patient involves the treatment of tendon or ligament injuries via direct intralesional injection. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] MSCs are also implanted in joints affected by osteoarthritis, cartilage damage, and meniscal damage. [4] [5] [6] 14, 15 Regional limb perfusion of MSCs may be useful to treat inaccessible lesions such as those affecting tendons within the foot, or to treat locally extensive disorders such as laminitis, diffuse tendon and ligament injuries, or multiple lesions within the same limb. 6, 16 All of these applications require that MSCs be injected through a needle or catheter; however, there is very limited information on the effect of needle or catheter diameter on equine MSCs.
Research efforts in regenerative medicine have largely focused on proof-of-principle in vitro studies with few longterm clinical trials. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Treatment protocols for each specific
application have yet to be defined. 2, 4, 6, 12 Very few controlled studies have been published to optimize delivery methods 1, 6, 11 and number of injected cells. 2, 4, 6, 12 Clinical application of equine MSCs typically rely on cells being shipped to practitioners from commercial or university laboratories. This practice prompted Bronzini et al. 1 therefore evaluated the effect of needle diameter (20-ga, 25-ga, and 30-ga needles as well as a 26-ga SL-10 microcatheter) and flow rate on rat and human MSC viability and cell surface markers. Whereas these variables had no effect on rat MSCs immediately or 24-hour post-injection, the viability of human MSCs was decreased 24 hours after injection through 30-ga and microcatheters. In addition, apoptotic and dead cell fractions correlated inversely with needle sizes. 18 Recently, Garvin et al. 19 reported that injecting equine MSCs through 23-ga, 21-ga, and 19-ga needles did not influence their viability or differentiation; however, apoptotic cells were more abundant when cells were injected through 23-ga and 21-ga needles compared to 19-ga and non-injected controls. The purpose of this study was to evaluate the effect of needle diameter on the viability of equine bone marrowderived MSCs when handled as recommended by Bronzini et al. 1 Variables that may affect viability such as the horse, cell size, passage, and needle shear damage creating cell debris were also evaluated. We hypothesized that cell viability would decrease as needle diameter decreases.
| M AT E RIA L S AN D M E T H ODS

| Bone marrow aspiration
All procedures were approved by the Cornell University Institutional Animal Care and Use Committee. Bone marrow was obtained from 5 adult Thoroughbred or Thoroughbred cross horses; 2 castrated males and 3 females, age 1-10. The horses were sedated, local anesthesia was instilled, and sternal bone marrow aspirates were obtained using an 11-ga Jamshidi bone marrow biopsy needle under sterile conditions. A total of 120 mL of bone marrow aspirate was collected from each horse into two 60-mL syringes each containing 25 000 units of heparin.
| Culture of MSCs
Each bone marrow aspirate was purified via Ficoll-Paque Plus (American Biosciences, Piscataway, New Jersey) gradient centrifugation. Cells were plated (10 000 cells/cm 2 ) and cultured at 378C at a 5% CO 2 , 95% air atmosphere, and 5% humidity. Media contained Dulbecco's modified Eagle's medium, 2 mM L-glutamine, penicillin (100 units/mL), streptomycin (100 units/mL), basic fibroblastic growth factor (bFGF, 1 ng/mL), and 10% FBS. Cells were grown to confluency, lifted with trypsin, and resuspended in medium (10% FBS, 10% dimethyl sulfoxide, 80% media), prior to cryopreservation at 5 3 10 6 cells/vial until use.
Cells were then thawed, washed, and plated in medium as described above. Cells were expanded to ffi 6 3 10 7 (passage 3) and ffi 6 3 10 7 (passage 4) for the first 2 horses.
Cells collected from the third horse was expanded to ffi 6 3 10 7 (passage 3) and those from the last 2 horses were expanded to ffi 6 3 10 7 (passage 2).
| Storage of MSCs
Cells were divided into 5 sample groups, with a duplicate per group, for a total of 10 samples ( Figure 1 ). For each sample, MSCs were washed with medium and PBS, centrifuged, and resuspended to 1 3 10 7 cells in 1 mL in PBS. 0.5 mL of cell suspension was individually pipetted into a cryovial. To mimic shipping of cells for clinical use, 1 cryovials were kept at room temperature for approximately 7 hours. During this time, cells settle out of suspension and form a soft pellet at the bottom of the cryovial.
| Needle aspiration and injection of MSCs
Two cryovials were used as controls and two were assigned to each hypodermic needle size: 20-ga 1 inch, 22-ga 1 inch, 23-ga 1 inch, and 25-ga 5/8 inch, respectively. The pellet of cells was resuspended by gently inverting the cryovial several times. For each needle size group, the suspended cells were aspirated through the needle into a 3 mL syringe and re-injected into the cryovial a total of 3 times immediately prior to counting. This step was designed to simulate the practice commonly followed by practitioners to resuspend cells prior to injection into the patient. Cells in the control group were aspirated with a micropipette (1000 mL).
| Viability of MSCs
Cell viability was assessed by staining cells with the supra vital dyes fluorescein diacetate (green fluorescence) and propidium iodide (red fluorescence), prior to examination under fluorescent microscopy. 20 Total and viable cell numbers were counted in replicate for each sample, including duplicates. Percent viability was calculated for each sample. Duplicates and replicate samples were averaged prior to statistical analysis.
To account for variability in time to cell processing, cell aspiration, staining, and counting were performed in the following order (groups A and B): control A, 20-ga A, 22-ga A, 23-ga A, 25-ga A; 25-ga B, 23-ga B, 22-ga B, 20-ga B, control B (Figure 1 ).
| Determination of equine MSC diameter
The range and average diameter of 100 MSCs was measured in control samples. Cell diameter was measured from microscopy images and calculated using quantitative image analysis in Adobe Photoshop CS4 ® Extended (Adobe Systems Inc, San Jose, California). The measurements were calibrated by measuring the length of one side of a small square in a hemocytometer in a microscopic image and setting it to the known length of one side of the small squares (0.25 mm). The distribution of cell sizes was subjectively observed during cell viability assessment with fluorescent microscopy.
| Flow cytometry
Unstained MSC samples were evaluated for the presence of cellular debris based on forward scatter (FSC) using a FACS Calibur flow cytometer (BD Biosciences, Mississauga, ON, Canada). Fifty thousand events were counted for all control and needle samples. Flow cytometry (FC) data were analyzed using FlowJo software (TreeStar Inc, Ashland, Oregon) to compare events with FSC consistent with debris versus intact cells. Since a single sheared cell could give rise to multiple debris events, these data were analyzed in terms of trends rather than absolute numbers or percentages.
| Statistical analysis
For each sample set, percent viability compared to control was determined. Data were analyzed with analysis of covariance (ANCOVA), with horse and passage number as covariates, followed by the Least Significant Difference (LSD) test for multiple comparisons. Analyses were performed using Statistix 9 software (Analytical Software, Tallahassee, Florida) and significance was set at P < .05.
| RE SU LTS
| Viability of MSCs aspirated through various diameter needles
MSC viability was greater in the 20-ga needle group compared to the 25-ga group (Figure 2 ; P 5 .03). No difference in MSC viability was found between cells injected through 20-ga, 22-ga, and 23-ga needles. Similarly, no difference was found between 22-ga, 23-ga, and 25-ga needle groups. Horse and MSC passage number did not influence MSC viability (P 5 .25 and .24, respectively).
| Size distribution of equine MSCs
Cell diameter ranged from 9.1 to 37.3 lm, with an average of 21.6 lm. Size distribution of viable cells was subjectively more heterogeneous after mixing cells in the control and larger diameter needle groups, including more cells at the larger end of the size range. As needle diameter decreased, viable cells appeared more homogeneous in size, with viable F IG UR E 2 Effect of needle diameter on MSC viability measured as a percentage of control cell viability. Bars represent mean 1/2 S.D. Superscript letters indicate significant differences in MSC viability between needle diameter groups (20-ga, 22-ga, 23-ga, 25-ga). ANCOVA, with horse and passage number as covariates, followed by LSD test for multiple comparisons was performed, significance was set at P < .05 
| MSC debris after aspiration through needles
The FC data were consistent with viability staining. Based on the evaluation of FSC, an indication of relative cell size, a larger percentage of events with size value range consistent with intact cells was present in 20-ga samples compared to 25-ga samples. The percentage of events in the debris gate tended to increase relative to those in the viable cell gate with decreasing needle gauge size. Figure 4 illustrates an example of FC data output, with a larger percentage of events in the intact cell gate in the control and 20-ga needle sample, compared to the 25-ga needle sample.
| DISCUSSION
The primary objective of this study was to determine the effect of injecting equine MSCs through different size needle diameters on cell viability. Larger MSCs are more likely to be sheared and killed when passed through smaller diameter needles, as indicated by the decrease in MSC viability injected through 25-ga compared to 20-ga needles. MSC viability did not vary significantly with horse or passage. Cell debris tended to increase as needle diameter decreased. The decreased cell viability observed in 25-ga needle in our study may result from the mechanical shear created by small-diameter needle as proposed by Tol et al. 17 and Walker et al. 18 Cell suspensions included fewer larger cells as the diameter of the needle decreased, and contained a greater number of non-viable cells. Viability of human MSCs was negatively affected by smaller needle diameters in a study, but this finding was not confirmed when human bone marrow mononuclear cells, whose diameter is smaller, were tested in another study. 17, 18 The equine MSCs tested in our study were larger than human MSCs, as their diameter averaged 21.6 lm. Based on these data, one should expect cells to be exposed to shear as needle diameter decreases, thereby generating cell debris. In that context, the lack of difference in MSC viability between the 20-ga, 22-ga, and 23-ga needles is intriguing. Comparing cell to needle diameters, one could reason that the 20-ga needle would leave a larger safety margin against cell damage compared to the smaller diameter needles evaluated. Viability tended to improve and cell debris tended to be less on FC when comparing the 20-ga to both the 22-ga and 23-ga needles in our study. These data converge with the increase in apoptotic cells reported by Gavin et al., 19 when comparing cell suspensions injected through 23-ga and 21-ga needles compared to 19-ga needles and non-injected controls. Combined, these results support the use of a 20-ga needle to administer stem cells suspensions. The proposed benefits, in terms of cell viability, should however be weighed against the size of associated needle tracks, the clinical relevance of which warrants further research. Shear stress is not only influenced by cross sectional area, but also varies with fluid flow, velocity, and the length of the channel. 19 Although flow rates were not measured in our study, the technique used to draw and inject the cell solution through the needle and syringe was kept as consistent as possible between samples, and was designed to simulate the handling of cell suspensions in the clinical setting. Standardizing flow between groups would inherently increase the 19 did not detect any difference in equine MSC viability or differentiation when passed through 23-ga, 21-ga, and 19-ga needles. However, they did not evaluate smaller needle sizes, nor did they test the influence of serial passes through the needle, as often done in practice. These factors were included in our study. Comparing the results of our study with Gavin's, needle diameter seems more important for inciting cell death than the method used to mix cells prior to injection. A 5/8 inch 25-ga needle was used in our study as this type of needle is routinely used in our hospital for superficial injections. However, the length of this needle is 3/8 inch shorter than the other needles included in our study. Although not evaluated, it is likely that cell viability would have been more severely affected if the 25-ga needle had been 1 inch long, as turbulent flow causes shear stress and is directly proportional to the length of the tube. 19 Injection pressure is another factor that could influence cell viability. No methods or devices are available to measure injection pressure in the clinical setting. Without such information, laboratory findings relating injection pressure to cell death would have no clinical significance. Injection pressure was therefore neither measured, nor controlled in our study. Rather, the study was designed to evaluate the influence of methods, including cell injection, currently used in clinical practice by the authors. Clinical applications of stem cell therapy, in particular those involving tendons and ligaments, require that healthy normal tissue be punctured with a needle or catheter to deliver the MSCs. Horses are often more reactive to the pain associated with insertion of larger needles so naturally, smaller diameter needles would be desirable to minimize pain of treatment administration. Needle tracks can sometimes be seen in tendons for months following the injection 7, 13 and, presumably, larger diameter needles would cause more tissue damage and needle track development. Although no evidence has linked the development of needle tracks with increased pain or loss of function, these tracks could serve as an escape route for MSCs away from the site of the lesion. These tracks could therefore jeopardize the retention of cells at the injection site, and attenuate their therapeutic effect. These potential disadvantages, combined with owners' concerns over needle tracks, support the use of the smallest needle diameter that will not damage the cells. Based on the results of our study, careful resuspension of the cells, through needles larger than 25-ga, is recommended. This study provides additional information toward establishing injection protocols for clinical applications of equine MSCs. While our study addresses one aspect of such protocols, ideal cell number and concentration, timing and frequency of administrations will warrant future research to optimize stem cell therapy. 
